Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
Sign Up to like & getrecommendations! Published in 2018 at "JACC: Basic to Translational Science"
DOI: 10.1016/j.jacbts.2018.01.010
Abstract: Canagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), was shown to reduce major adverse cardiovascular events in the recent CANVAS (CANagliflozin cardioVascular Assessment Study) program [(1)][1]. Canagliflozin treatment was, however, also associated with a significant increase… read more here.
Keywords: blood flow; canagliflozin improves; improves recovery; canagliflozin ... See more keywords